Evolution of neutralizing antibodies through vaccination and breakthrough infections in the era of COVID-19 endemicity.

导出原文传递

翻译打印收藏纠错

作者： Jinyoung,Yang ^[1] ; Hye-Jin,Kim ^[2] ; Jun-Won,Kim ^[3] ; Jin Yang,Baek ^[1] ; Young Jae,Lee ^[4] ; Ju-Yeon,Choi ^[2] ; Su-Hwan,Kim ^[2] ; Hyeonji,Jeong ^[2] ; Eun Joo,Chung ^[2] ; Gi-Eun,Rhie ^[2] ; Byoung Kwon,Park ^[2] ; So-Young,Lee ^[3] ; Kyong Ran,Peck ^[3] ; Byoungguk,Kim ^[1] ; Jae-Hoon,Ko ^[2]

作者单位： Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[1] Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju, Republic of Korea. ^[2] Center for Emerging Virus Research, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea. ^[3] Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea. ^[4]

关键词 SARS-CoV-2 variants antibodies breakthrough infections immunoglobulins intravenous neutralizing vaccination

主题词人类(Humans);抗体, 中和(Antibodies, Neutralizing);免疫球蛋白类, 静脉内(Immunoglobulins, Intravenous);疾病大流行(Pandemics);抗体, 病毒(Antibodies, Viral);接种(Vaccination)

DOI 10.1002/jmv.29285

PMID 38054545

发布时间 2024-01-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交